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Rotterdam, the Netherlands
Perioperative myocardial infarctions are the predominant cause of morbidity and mortality in patients undergo-
ing noncardiac surgery. The pathophysiology of perioperative myocardial infarction is complex. Prolonged myo-
cardial ischemia due to the stress of surgery in the presence of a hemodynamically significant coronary lesion,
leading to subendocardial ischemia, and acute coronary artery occlusion after plaque rupture and thrombus for-
mation contribute equally to these devastating events. Perioperative management aims at optimizing the pa-
tient’s condition by identification and modification of underlying cardiac risk factors and diseases. During recent
decades there has been a shift from the assessment and treatment of the underlying culprit coronary lesion to-
ward a systemic medical therapy aiming at prevention of myocardial oxygen supply demand mismatch and coro-
nary plaque stabilization. Beta-blockers, statins, and aspirin are widely used in this setting. The role of prophylac-
tic coronary revascularization has been restricted to the same indications as the nonoperative setting. Therefore
pre-operative cardiac testing is recommended only if test results will change perioperative management. In addi-
tion to the limited perioperative period, physicians should benefit from this opportunity to initiate lifestyle
changes and medical therapy to lessen the impact of cardiac risk factors, as patients should live long enough
after the operation to enjoy the benefits of surgery. (J Am Coll Cardiol 2008;51:1913–24) © 2008 by the
American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.03.005o
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aatients undergoing major noncardiac surgery are at signif-
cant risk of cardiovascular morbidity and mortality. It is
stimated that in Europe 40 million surgical procedures are
erformed annually with a post-operative myocardial infarc-
ion (MI) rate of 1% (400,000), and a cardiovascular
ortality rate of 0.3% (133,000). Although the periopera-
ive event rate has declined over the past 30 years as a
onsequence of recent developments in anesthesiologic and
urgical techniques (e.g., regional anesthesia and endovas-
ular treatment modalities), perioperative cardiac complica-
ions remain a significant problem. A pooled analysis of
everal large studies found a 30-day incidence of cardiac
vents (perioperative myocardial infarction [PMI] or cardiac
eath) of 2.5% in unselected patients over the age of 40
ears (1). These complications were higher in vascular
urgery patients, who had an incidence of 6.2% for cardiac
vents (2). The risk of perioperative cardiac complications is
he summation of the individual patient’s risk and cardiac
tress related to the surgical procedure. In addition, the
ncidence is also related to the post-operative surveillance
creening adopted, as the great majority of cardiac events are
symptomatic (Fig. 1). Studies that routinely assessed post-
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ccepted March 4, 2008.perative cardiac isoenzymes (i.e., troponin T or I measure-
ents) detected an incidence of PMI up to 25% in high-risk
atients (3,4).
According to the World Health Organization, the global
pidemic of cardiovascular disease will not only increase, but
ill also shift from developed to developing nations. It is
urther estimated that in the second half of the 21st century,
ore than 1 in 4 individuals will be 65 years of age or older.
n the past, major surgery was rarely performed on patients
n their ‘80s or ‘90s. Nowadays, many major surgical
nterventions are performed in this very elderly population.
recent study of 1,351 patients undergoing noncardiac
urgery showed that the rate of cardiac events increased with
dvanced age, independent of other clinical variables, in
hose patients with myocardial perfusion abnormalities dur-
ng stress scintigraphy (5). With the growing elderly popu-
ation, an increased incidence of underlying cardiovascular
isease, and the availability of advanced surgical techniques,
hese noncardiac surgery patients continue to demand our
ttention.
athophysiology of PMI
lthough the pathophysiology of PMI is not entirely clear,
t is now well accepted that coronary plaque rupture, leading
o thrombus formation and subsequent vessel occlusion, is
n important cause of acute perioperative coronary syn-
romes. This is similar to the nonoperative setting. The
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Pre-Operative Risk Assessment May 20, 2008:1913–24perioperative surgical stress re-
sponse includes a catecholamine
surge with associated hemody-
namic stress, vasospasm, reduced
fibrinolytic activity, platelet acti-
vation, and consequent hyperco-
agulability (6). In patients with
significant coronary artery dis-
ease (CAD), PMI may also be
caused by a sustained myocardial
supply/demand imbalance due to
tachycardia and increased myo-
cardial contractility (6).
Episodes of perioperative ST-
segment depression, indicating
subendocardial myocardial isch-
mia, have been described in up to 41% of vascular surgery
atients, mostly occurring within the first 2 days after
urgery (7). The association of PMI with myocardial isch-
mia and nontransmural or circumferential subendocardial
nfarction supports this mechanism. Landesberg et al. (8)
emonstrated that 85% of postoperative cardiac complica-
ions were preceded by prolonged ST-segment depression.
leisher et al. (9) found that 78% of patients with cardiac
omplications had at least 1 episode of prolonged myocar-
ial ischemia (i.e., 30 min), either before or at the same
ime as the cardiac event. In the majority of cases, it presents
ithout Q waves. The hypothesis that ST-segment depres-
ion can lead to PMI is further supported by increased
roponin T levels during or shortly after prolonged ST-
egment depression ischemia (10).
ST-segment elevation–type ischemia is considered to be
elatively uncommon, confirmed by the incidence (12%) of
ntraoperative ST-segment elevation in a study by London
t al. (11). Few data exist on this topic. As demonstrated in
he autopsy study by Dawood et al. (12), 55% of the fatal
Figure 1 Perioperative Cardiac Events
The incidence of perioperative cardiac events in major noncardiac
surgery. Data from Poldermans et al. (19). MI  myocardial infarction.
Abbreviations
and Acronyms
ACC  American College of
Cardiology
AHA  American Heart
Association
ASA  acetylsalicylic acid
CAD  coronary artery
disease
MI  myocardial infarction
MPS  myocardial
perfusion scintigraphy
PMI  perioperative
myocardial infarctionpMIs have direct evidence of plaque disruption defined as
ssure or rupture of plaque and hemorrhage into the plaque
avity. Similar autopsy results were found in the study by
ohen and Aretz (13); a plaque rupture was found in 46%
f patient with post-operative MI. Time-to-death interval
n patients with plaque rupture was significantly longer than
n patients without plaque rupture.
In a submitted study of Feringa and colleagues (personal
ommunication, February 2008) 401 vascular surgery pa-
ients were evaluated by continuous 12-lead electrocardio-
raphic monitoring during surgery and studied for the
resence and location of ischemia. The relationship with the
re-operatively assessed culprit coronary artery lesion using
oninvasive cardiac imaging was studied. In patients with
erioperative ST-segment depression, the location corre-
ponded with the pre-operatively assessed coronary lesion in
9%, and only in 53% of those with ST-segment elevation
p  0.001). This study showed one of the limitations of
re-operative cardiac risk assessment focusing on the identifi-
ation of the culprit coronary artery lesion. Using cardiac
esting, one can identify the patient at risk; however, the
ocation of the PMI is difficult to foresee, owing to the
npredictable progression of (asymptomatic) coronary artery
esions toward unstable plaques owing to the stress of surgery.
erioperative Management
isk stratification. The first step in pre-operative care is
n adequate identification of patients at risk for periopera-
ive cardiac events. In the past decades, several risk indexes
ave been developed in this context to stratify surgical
atients. Goldman et al. (14) in 1977 developed the first
ultifactorial risk index specifically for cardiac complica-
ions. The risk index was developed in a large surgical
opulation and included 9 independent risk factors corre-
ated with serious or fatal cardiac complications (14). Sub-
equently, this index was modified by Detsky et al. (15) in
986, who used a Bayesian approach using pre-test proba-
ilities and presented the modified cardiac risk index in a
imple nomogram. The Revised Cardiac Risk Index, devel-
ped in 1999 by Lee et al. (16), is nowadays the most widely
sed model of risk assessment in noncardiac surgery. This
ndex identifies 6 predictors of major cardiac complications:
igh-risk surgery, ischemic heart disease, congestive heart
ailure, cerebrovascular disease, insulin-dependent diabetes
ellitus, and renal failure. Based on the presence of none, 1,
, or 3 predictors, the rate of major cardiac complications
n the validation cohort (n  1,422) was estimated to be
.4%, 0.9%, 7%, and 11%, respectively. Recently, it was
emonstrated in 108,593 patients undergoing all types of
oncardiac surgery that this Revised Cardiac Risk Index was
ndeed predictive of cardiovascular mortality but could be
ubstantially improved by adding age and a more detailed
lassification of type of surgical procedure (C-statistic im-
roved from 0.63 to 0.85) (17).
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May 20, 2008:1913–24 Pre-Operative Risk Assessmentoninvasive testing. Once the pre-operative risk assess-
ent indicates an increased cardiac peri- or post-operative
isk, further cardiac testing is warranted. The predominant
heme of testing is the impact of test results on perioperative
anagement; if test results will not influence management,
esting is not recommended (18). According to the 2007
uidelines of the American College of Cardiology (ACC)
nd American Heart Association (AHA), patients with
ctive cardiac conditions (i.e., unstable coronary syndromes,
ecompensated heart failure, significant arrhythmias, or
evere valvular disease) have to be evaluated and treated
efore surgery (18). Pre-operative cardiac testing for elective
urgery is reasonable for patients with 3 clinical risk
actors and poor functional capacity who require vascular
urgery (Class IIa) (Table 1, Fig. 2). Pre-operative testing
ay be considered in patients with at least 1 to 2 clinical
isk factors and poor functional capacity who require
ntermediate-risk noncardiac surgery and in patients with at
east 1 to 2 clinical risk factors and good functional capacity
ho are undergoing vascular surgery (Class IIb). Noninva-
ive testing is not recommended for patients without clinical
isk factors undergoing intermediate- or low-risk noncar-
iac surgery (Class III).
Although pre-operative testing may be considered for
atients with 1 or 2 risk factors scheduled for vascular
urgery, the results of the randomized, multicenter
ECREASE (Dutch Echocardiographic Cardiac Risk
valuation Applying Stress Echo)-II study showed differ-
ntly. If patients received beta-blockers with tight heart rate
ontrol, the perioperative cardiac event rate was already so
educed that test results and subsequent alteration in peri-
perative management were redundant (19). No differences
n cardiac death and MI at 30 days were observed between
70 patients assigned to no testing versus cardiac stress
esting (1.8% vs. 2.3%; odds ratio [OR] 0.78, 95% confi-
ence interval [CI] 0.28 to 2.1). Importantly, pre-operative
esting delayed surgery for more than 3 weeks.
Several noninvasive and exercise stress tests are available
or perioperative risk assessment. The most commonly used
tress test for detecting myocardial ischemia is the treadmill
r cycle ergometer test. These tests provide an estimate of
he functional capacity and hemodynamic response and
etect myocardial ischemia by ST-segment changes. The
ccuracy varies widely among studies (20). However, an
mportant limitation in patients undergoing noncardiac
ACC/AHA Classification of Recommendations
Table 1 ACC/AHA Classification of Recomm
Class I Conditions for which there is ev
treatment is beneficial, usef
Class II Conditions for which there is co
usefulness/efficacy of a pro
Class IIa Weight of evidence/opinion is i
Class IIb Usefulness/efficacy is less well
Class III Conditions for which there is ev
is not useful/effective, and iACC  American College of Cardiology; AHA  American Heart Association.urgery is the frequently limited exercise capacity in the
lderly and the presence of claudication, arthrosis, or
hronic obstructive pulmonary disease. Consequently, non-
hysiologic stress tests, such as dobutamine stress echocar-
iography or dipyridamol myocardial perfusion scintigraphy
MPS), are recommended in patients with limited exercise
apacity.
During dobutamine stress echocardiography, incremental
oses of dobutamine mimic physical exercise by increasing
yocardial contractility and heart rate, leading to enhanced
xygen demand. In a region supplied by a hemodynamically
ignificant coronary artery lesion, myocardial ischemia is
nduced, leading to contractile dysfunction that can be
ssessed by echocardiography as new wall motion abnor-
alities. Dobutamine stress echocardiography is an estab-
ished test to predict perioperative events in patients under-
oing surgery, with a high negative predictive value and a
oderate positive predictive value (18,20–25).
Myocardial perfusion scintigraphy is a widely used imag-
ng technique for pre-operative evaluation. This technique
nvolves intravenous administration of a small quantity of a
adioactive tracer such as a technicum99m-labeled radio-
harmaceutical. Images are obtained at rest and during
asodilator stress. Detection of CAD is based on a differ-
nce in blood flow distribution during vasodilator stress,
nduced by insufficient coronary blood flow increment
ttributed to coronary stenosis. A positive MPS is associated
ith increased risk of peri- and post-operative cardiac
omplications. Studies indicate that MPS is highly sensitive
or prediction of cardiac complications, but the specificity
as been reported as less satisfactory (20,21,26,27).
Although no head-to-head comparisons of large numbers
f patients have been performed, 2 large meta-analyses have
ompared these techniques with respect to sensitivity and
pecificity. The studies by Kertai et al. (20) and Beattie et al.
21) concluded that stress echocardiography was slightly
avorable to predict post-operative events owing to the
etter negative predicative characteristics. However, the
iterature gives no definite answer in selecting the most
ccurate test. The choice of the test should therefore be
ased on the center’s experience and short-term availability
s highlighted in the ACC/AHA guidelines (18).
rophylactic revascularization. Prophylactic pre-operative
oronary revascularization of the culprit lesion may prevent
erioperative complications in patients with significant
tions
for and/or general agreement that the procedure or
effective.
g evidence and/or a divergence of opinion about the
or treatment.
r of usefulness/efficacy.
lished by evidence/opinion.
and/or general agreement that the procedure/treatment
e cases may be harmful.enda
idence
ul, and
nflictin
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n favo
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Pre-Operative Risk Assessment May 20, 2008:1913–24AD scheduled for surgery. However, the value of prophy-
actic revascularization is controversial (28–30). Whereas
ormer evidence was based on small observational studies
nd expert opinions, 2 recent randomized controlled trials
ave clarified this issue. The CARP (Coronary Artery
evascularization Prophylaxis) trial conducted by McFalls
t al. (31) was the first randomized trial that investigated the
enefit of coronary revascularization before elective major
ascular surgery. In that study, 510 patients with significant
rtery stenosis were randomized to either revascularization
r no revascularization before surgery. Within 30 days, no
eduction in the number of MIs or deaths or in lengths of
ospital stay was observed. Furthermore, as illustrated in
igure 3, long-term outcome in patients who underwent
re-operative coronary revascularization was similar to pa-
Figure 2 Recommendations for Noninvasive Stress Testing Acc
Green bars indicate no recommendation of noninvasive stress testing and that pa
be considered if it will change management (class IIb); and the red bar indicates a
lege of Cardiology/American Heart Association. Data from Fleisher et al. (18).
Figure 3 Prophylactic Coronary Revascularization
Results of the CARP (Coronary Artery Revascularization Prophylaxis) study: long-
term survival among patients assigned to undergo coronary artery revascularization
or no revascularization. Reprinted with permission from McFalls et al. (31).dients who received optimized medical therapy (22% vs. 23%
ortality; relative risk [RR] 0.98, 95% CI 0.70 to 1.37).
ecause the majority of patients in the CARP trial had only
- or 2-vessel disease with a preserved left ventricular
unction, the optimal pre-operative management for pa-
ients with left main disease, severe left ventricular dysfunc-
ion, unstable angina pectoris, and aortic stenosis was not
etermined. In a recent study evaluating vascular surgery
atients with predominantly 3-vessel disease, similar find-
ngs were obtained (32). The incidence of the composite
nd point of all-cause mortality and MI at 30 days was 43%
ersus 33% (OR 1.4, 95% CI 0.7 to 2.8) and at 1 year was
9% versus 44% (OR 1.2, 95% CI 0.7 to 2.3). Both studies
uggest that prophylactic coronary revascularization of
ardiac-stable patients provides no benefit for immediate
ost-operative outcome, although the studies were not
ignificantly powered to detect differences in outcome. In
ccordance with this evidence, the new ACC/AHA guide-
ines indicate that routine prophylactic coronary revascular-
zation is not recommended in patients with stable CAD
efore noncardiac surgery (18).
Another important clinical situation is the management
f patients with previous coronary stenting undergoing
oncardiac surgery (33). The risk of perioperative stent
hrombosis in these patients is increased by the noncardiac
urgical procedure, especially when surgery is performed
arly after stent implantation and particularly if dual anti-
latelet therapy is discontinued. When possible, it is advised
o delay surgery until after the time window that requires
ual antiplatelet therapy. The new ACC/AHA guidelines
ecommend, based on expert opinion, 30 to 45 days for
are-metal stents and 1 year for drug-eluting stents (18).
erioperative Management—New Insights
he beneficial effect of a pre-operative localized treatment
f a coronary stenosis is hampered because of the unpre-
g to the ACC/AHA Guidelines (2007)
can go directly to surgery; orange bars indicate patients for whom testing may
IIa recommendation for noninvasive stress testing. ACC/AHA  American Col-ordin
tients
classictable progression of a nonsignificant coronary lesion
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May 20, 2008:1913–24 Pre-Operative Risk Assessmentoward plaque rupture, thrombus formation, and subsequent
oronary artery occlusion. Plaque instability is driven by the
tress of surgery. Systemic therapy with medical treatment
iming at plaque stabilization therefore seems promising for
erioperative as well as long-term risk reduction. Perioper-
tive beta-blockers, statins, and aspirin have all shown a
ignificant benefit in decreasing cardiac mortality and mor-
idity (34–38). These effects can be divided into acute and
hronic effects.
eta-blocker therapy. Beta-adrenergic receptor antago-
ists (beta-blockers) are divided into 1-selective and non-
elective (1 and 2) adrenoreceptor blockers. Atenolol,
etoprolol, and bisoprolol, all 1-selective blockers, are
ommonly used for perioperative care. The classic idea of
he benefit of beta-blocking agents is its effect on restoring
he oxygen supply/demand mismatch. However, the com-
lexity of the interactions among the heart, the sympathetic
ervous system, and inflammation also contributes to the
enefit of beta-blockade (39). This latter effect is supposed
o evolve only after some time.
Although nowadays widely prescribed, there is still con-
iderable debate about the protective effect of beta-blockers,
specially after the results of the POISE (Perioperative
schemic Evaluation) trial became available (40). Some
tudies showed a clear evidence in favor of beta-blocker use
n the perioperative period (35,37), although other studies
ailed to demonstrate a cardioprotective effect (41–43). A
ecent large meta-analysis by Schouten et al. (44) included
5 studies (1,077 patients) and showed a significant bene-
cial effect of beta-blockers in noncardiac surgery patients
Fig. 4). The recently presented POISE study showed a
enefit of high-dose metoprolol controlled-release therapy
n the risk of MI but, importantly, at the cost of an
ncreased risk of stroke and overall mortality (40,45). Dif-
erent explanations exist regarding the conflicting evidence
or perioperative beta-blocker use. In particular, the initia-
ion time and dose of beta-blocker therapy, the type of
eta-blocker, dose adjustments for heart rate control, and
Figure 4 Perioperative Beta-Blocker Therapy
Comparison of patients treated with perioperative beta-blocker therapy versus no d
CI  confidence interval; MI  myocardial infarction; OR  odds ratio; Rx  treatmhe patients’ underlying cardiac risk are important factors
hat may relate to the effectiveness of therapy.
NITIATION TIME. It is unclear whether the effect on coro-
ary plaque stabilization, in contrast to heart rate control,
an be achieved instantly after beta-blocker start. The onset
f beta-blocker therapy before surgery in studies evaluating
he cardioprotective effect differs considerably, from months
o just hours before operation. Mangano et al. (35) con-
ucted the first randomized controlled trial investigating the
ffect of beta-blockers in patients undergoing noncardiac
urgery. In that trial, 200 patients with known or suspected
AD were randomized for atenolol or placebo just before
he induction of anesthesia. No difference in perioperative
ardiac events was observed, although the incidence of
lectrocardiographically assessed ischemia was reduced. The
AVS (Metoprolol After Vascular Surgery) trial random-
zed 496 patients to metoprolol or placebo starting 2 h
efore surgery until hospital discharge or a maximum of 5
ays after surgery (43). No significant differences in out-
ome were observed at 30 days after surgery or after 6
onths. In the POBBLE (Perioperative Beta-Blockade)
rial, 103 patients undergoing vascular surgery who were
andomized to metoprolol or placebo, starting less than 24 h
efore surgery until 7 days after, also showed no beneficial
ffect on 30-day cardiovascular outcome (41). Within 30
ays, cardiovascular events occurred in 32% and 34% pa-
ients in the metoprolol and placebo groups, respectively
adjusted RR 0.87, 95% CI 0.48 to 1.55). The DIPOM
Diabetic Postoperative Mortality and Morbidity) trial,
hich started therapy at the earliest in the evening before
ajor noncardiac surgery, again showed no improved 30-
ay outcome (42). The POISE trial randomized patients to
eceive either controlled-release metoprolol or placebo start-
ng 2 to 4 h before surgery and continued for 30 days. In
ontrast to these studies, the DECREASE-I trial started
isoprolol at an average of 37 (range 7 to 89) days before
urgery in 112 high-risk patients. In this period, careful
placebo.
eprinted, with permission, from Schouten et al. (44).rug or
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Pre-Operative Risk Assessment May 20, 2008:1913–24itration of bisoprolol therapy was performed. That study
howed a 10-fold reduction in incidence of perioperative
ardiac death and MI versus placebo (3.4% vs. 34%;
 0.001) (37).
The importance of the initiation time of beta-blocker
herapy before surgery can be argued by the pathophysiology
f PMI. The acute effects of beta-blockade include the
eduction of myocardial oxygen demand by a decrease in
eart rate, systolic pressure, and ventricular contractility.
therwise, the suggested effect of beta-blockers on coronary
laque stabilization may be related to anti-inflammatory
roperties and possibly only be observed after prolonged
se. Beta-blockade has been shown to decrease the level of
nflammatory cytokines in both the myocardium and the
ystemic circulation (46–48). A study in patients with acute
I demonstrated that beta-blocker treatment reduced in-
ammatory responses only after 48 h of treatment (49).
Although the study of Mangano et al. (35) did not
emonstrate a perioperative effect, atenolol use was associ-
ted with significantly lower mortality rates at 6 months
fter discharge (0% vs. 8%; p  0.001), over the first year
3% vs. 14%; p  0.005), and over 2 years (10% vs. 21%;
 0.019). Another randomized trial also showed benefit
f beta-blocker use on the long term, even up to 30 months
37). These findings support the hypothesis that not all
ffects of beta-blockers are achieved immediately after
nitiation of therapy. The long-term beneficial effects of
eta-blockers were recently confirmed by a study which
emonstrated a decreased progression of coronary athero-
clerosis in patients receiving beta-blockers. Sipahi et al.
50) performed a pooled analysis of individual patient data
rom 4 intravascular ultrasonography trials to investigate the
elationship between concomitant beta-blocker treatment
nd the progression of coronary atherosclerosis. The use of
eta-blockers was significantly associated with a decrease of
he atheroma volume at follow-up, whereas this was not
hanged in patients without beta-blockers. In addition, it
eems to be crucial to continue beta-blockers in the periop-
rative period. It has been shown that perioperative with-
rawal of beta-blocker therapy was associated with a 2.7-
old increased risk of 1-year mortality compared with
atients not using beta-blockers (51).
YPE. The predominant perioperative cardioprotective ef-
ect is regulated by 1-adrenoreceptor blockade. The peri-
perative period is associated with high adrenaline and
oradrenalin levels (52,53), creating a potentially dangerous
ituation in the presence of vulnerable plaques. The danger
as 2 aspects: a hemodynamic effect and a stimulation of the
nflammatory process. The hemodynamic risk is associated
ith increased heart rates and blood pressure associated
ith high sympathetic nerve activity (7). The beta-blocker
enefit could thus clearly be operating via its ability to lower
eart rate. Blood pressure and velocity of blood flow rise
nder the influence of high catecholamine activity, and so
eta-blocker normalizes turbulent flow and vessel wall shear oorces. However, blocking both 1- and 2-receptors in the
resence of raised adrenaline levels during surgery will lead
o uncontrolled alpha stimulation and a subsequent adverse
ise in blood pressure (54). Metoprolol and atenolol, which
re only moderately 1-selective, may increase myocardial
xygen demand and might therefore be less recommended
han the highly 1-selective bisoprolol. In the same vein, the
nflammatory process is exacerbated by high noradrenalin
evels (55), undoubtedly acting through 1-receptor overac-
ivity, which increases inflammation, necrosis, apoptosis,
nd matrix metalloproteinase activity (56). Interestingly
2-receptor overactivity inhibits the inflammatory necrotic/
poptotic process (57), thus making 2-blockade unwelcome.
The different beta-blockers have various plasma half-lives
nd peak ratios. Bisoprolol and atenolol are long-acting
gents with half-lives of 10 to 11 h and 6 to 7 h, respectively,
hereas metoprolol has a short duration of action of about
.5 h. A study by Redelmeier et al. (58) in elderly patients
ndergoing elective surgery reported that long-acting beta-
lockers are associated with higher cardioprotective benefits
han short-acting beta-blockers in the perioperative period.
n patients with CAD/unstable plaques, beta-blockers with
hort half-lives will increase the risk of a cardiovascular
vent on sudden withdrawal (51,59). In the acute absence of
2-blockade, the up-regulated 1-receptors plus high cate-
holamine levels would be a dangerous mix. Therefore,
ong-acting beta-blockers, such as bisoprolol, will be safer
han agents with short half-lives (21).
OSING AND TIGHT HEART RATE CONTROL. In addition to
he initiation time before surgery and type of beta-blocker,
ose adjustment for heart rate control is important. Raby
t al. (60) were the first to show positive results on strict
eart rate control in 26 patients undergoing major noncar-
iac surgery. A recent study demonstrated in 272 patients
hat higher doses of beta-blockers and tight heart rate
ontrol were associated with reduced perioperative myocar-
ial ischemia, troponin T release, and improved long-term
utcome (Fig. 5) (61). Accordingly, the new ACC/AHA
uidelines on perioperative care strongly recommend
chieving and maintaining a heart rate of 60 to 65 beats/min
18). Tight heart rate control will increase the likelihood
hat a patient will receive the benefit of beta-blockade.
The POISE trial initiated randomized treatment of
ontrolled-release metoprolol just before surgery, and the
aximum recommended therapeutical dose of metoprolol
400 mg) was already achieved within the first day of surgery
45). Medication was continued at 200 mg daily afterwards.
his is in contrast to the DECREASE studies, where a low
ose of bisoprolol at an average 12.5% of maximum recom-
ended therapeutical dose was carefully up-titrated during
mean period of 30 days. The primary findings of the
OISE trial were a reduction of perioperative MI by
igh-dose metoprolol controlled-release therapy, but an
xcess of overall mortality (40). They observed an incidence
f stroke of 1% in the group randomized to metoprolol
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May 20, 2008:1913–24 Pre-Operative Risk Assessmentompared with an incidence of 0.4% in the DECREASE
tudies. Several issues have to be clarified in the POISE
tudy to interpret their findings properly. The increased
ncidence of ischemic stroke in the POISE study in com-
ination with intraoperative bradycardia and hypotension
uggests an overtreatment effect. The lesson from the
OISE study might be that beta-blockers should be care-
ully titrated and that the stopping rule of a systolic blood
ressure of 100 mm Hg for metoprolol controlled-release
herapy might be hazardous in elderly patients with a history
f stroke.
ARDIAC RISK. Another important issue is the identifica-
ion of surgical patients who may benefit from beta-blocker
herapy. The evidence of the beneficial effect of beta-
lockers is strongest in high-risk patients. Lindenauer et al.
62) performed a retrospective cohort study of 782,969
atients who underwent major noncardiac surgery to inves-
igate the association of beta-blockers with perioperative
utcome. They observed a relationship between cardiac risk
nd the effect of perioperative beta-blocker use. Beta-
locker use showed no benefit or possible harm in low-
isk patients but had a significant beneficial effect in high-
isk patients. Important to note is that in the MAVS trial,
ost patients were at low risk for complications, as almost
0% had a Revised Cardiac Risk Index score of only 1 (43).
he negative DIPOM trial also included many low-risk
atients (42). Additionally, in contrast to the ACC/AHA
uidelines (18), in the Juul et al. study (42), major noncar-
iac surgery was defined as surgery with an expected
uration of 1 h.
UIDELINES. Recently, the ACC and AHA introduced a
uideline update on perioperative beta-blocker therapy (63).
Figure 5 Heart Rate Control
Mean heart rate in relation to myocardial ischemia assessed by continuous
electrocardiography and troponin T release. Data from Feringa et al. (61). ECG 
electrocardiogram.hese recommendations are summarized in Table 2. The wlass I recommendations of these guidelines are to continue
eta-blocker therapy in patients already receiving beta-
lockers and to start patients with a positive stress test
n beta-blockers. Furthermore, beta-blocker therapy is
robably recommended for patients undergoing vascular
urgery in which pre-operative assessment identifies coro-
ary heart disease or high cardiac risk as defined by the
resence of multiple clinical risk factors (Class IIa). The
ame class of recommendation holds for patients in whom
re-operative assessment identifies coronary heart disease or
igh cardiac risk and who are undergoing intermediate- or
igh-risk procedures. Class IIb recommendations include
atients with intermediate cardiac risk who are undergoing
ntermediate- or high-risk procedures and patients with low
ardiac risk who are scheduled for vascular surgery and are
urrently not on beta-blockers.
Further large randomized trials are definitely needed to
ive more conclusive recommendations regarding beta-
locker therapy for patients undergoing noncardiac surgery
n different risk groups. The ongoing DECREASE-IV
tudy may give more insight into the optimal pharmaceuti-
al prevention with beta-blockers and statins of periopera-
ive cardiovascular complications (64).
tatins. Statins are widely prescribed in patients with or at
isk for CAD, because of their well-established lipid-
owering capacity. Statins have other important beneficial
ffects on atherosclerotic vascular disease, which are known
s its pleiotropic effects (65). These effects include athero-
clerotic plaque stabilization, oxidative stress reduction, and
decrease of vascular inflammation. In human carotid
laques, statins have been demonstrated to decrease lipids,
ipid oxidation, inflammation, matrix metalloproteinases,
nd cell death and to increase tissue inhibitors of metallo-
roteinases and collagen (66). These properties of statins may
tabilize coronary artery plaques, thereby preventing plaque
upture and subsequent MI in the perioperative period.
Different large clinical trials in patients with CAD have
hown a beneficial effect of statins. The 4S (Scandinavian
imvastatin Survival Study) demonstrated that simvastatin
n CAD patients was safe and improved long-term outcome
67). Importantly, that same research group showed that the
eneficial effect of simvastatin is not restricted to coronary
therosclerosis, as statin use was also associated with a
eduction of new or worsening intermittent claudication and
ther noncoronary ischemic symptoms and signs (68).
hese positive observations of statin therapy are also ob-
erved during vascular surgery (Fig. 6). A retrospective
ase-control study among 2,816 patients who underwent
ajor noncardiac vascular surgery was the first study to
how a benefit of statins in the perioperative period. That
tudy demonstrated a 4-fold significant reduction in all-
ause mortality (adjusted OR 0.22, 95% CI 0.10 to 0.47)
36). A year later, the first prospective, placebo-controlled,
linded, randomized clinical trial evaluating the effects of
tatin therapy on perioperative cardiovascular complications
as reported by Durazzo et al. (34). They randomized 100
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Pre-Operative Risk Assessment May 20, 2008:1913–24atients to either 20 mg atorvastatin or placebo for 45 days.
he combined cardiovascular end point in the trial was
efined as cardiac death, nonfatal MI, stroke, or unstable
ngina pectoris. After 6 months of follow-up, the incidence
f cardiovascular events was more than 3-fold higher with
lacebo than with atorvastatin (26% vs. 8%; p  0.031).
Different retrospective trials have also evaluated the
ffects of statin therapy on perioperative complications in
atients undergoing noncardiac surgery (69–71). Linde-
auer et al. (70) performed a large retrospective cohort study
f 780,591 patients undergoing major noncardiac surgery at
29 hospitals. After correction for numerous baseline dif-
erences, the 70,159 statin users had a 1.4-fold reduced risk
f in-hospital mortality (adjusted OR 0.62, 95% CI 0.58 to
.67). The STARRS (Statins for Risk Reduction in Sur-
ery) study assessing the effect of statins on cardiac compli-
ations in patients undergoing noncardiac vascular surgery
lso supported the use of perioperative statin therapy (71).
n that retrospective study cohort of 1,163 patients, statin
sers had a significantly lower perioperative complication
ate than patients without statin therapy (adjusted OR 0.52,
5% CI 0.35 to 0.77). The protective effect of statin use was
imilar across the different risk group categories and per-
isted after adjusting for the propensity of statin use. Several
ystematic review articles have demonstrated supportive
vidence of statin therapy (72–74).
Figure 6 Perioperative Statin Therapy
Results of the effect of perioperative statin therapy in different studies. CI  confi
ecommendations for Perioperative Beta-Blocker Therapy Accordin
Table 2 Recommendations for Perioperative Beta-Blocker Ther
Surgery No Clinical Risk Factors >1 Clinical Risk Fa
Vascular Class IIb, Level of Evidence: B Class IIa, Level of Evide
Intermediate risk — Class IIb, Level of Evide
Low risk — —
dapted from Fleisher et al. (18). Level of evidence according to the ACC/AHA: A data derived fro
tudies; C only consensus opinion of experts, case studies, or standard-of-care. *Applies to patie
eart disease.
CHD  coronary heart disease; other abbreviations as in Table 1.In addition, the long-term benefit of statins was reported
n patients undergoing successful abdominal aortic aneu-
ysm surgery. Kertai et al. (75) followed 510 patients who
urvived aortic aneurysm surgery for a median of 4.7 years.
AFETY OF PERIOPERATIVE STATIN USE. A major concern
f statin therapy is the potential side effects, such as
tatin-induced myopathy and rhabdomyolysis. Periopera-
ively, patients might be unaware of these symptoms, owing
o sedation, or they are erroneously associated with post-
perative surgery complaints. In a retrospective study,
chouten et al. (76) studied 981 consecutive patients un-
ergoing major vascular surgery without PMI to assess the
otential risk of myopathy associated with statin therapy.
tatin therapy was initiated before surgery in a total of 44
atients with elevated cholesterol levels and continued in
82 patients already taking statin therapy. Blood samples
ere taken and patients were monitored for muscle com-
laints at days 1, 3, and 7 after surgery and at discharge.
yopathy was defined as creatine kinase elevations with or
ithout observed muscle complaints. After correcting for
ardiac risk factors and clinical risk factors for myopathy,
ength of surgery remained the only factor independently
ssociated with creatine kinase elevations. Rhabdomyolysis,
efined as creatine kinase levels above 10 times the upper
imit of normal, was not observed. Considering that the risk
interval; OR  odds ratio.
the ACC/AHA Guidelines
ccording to the ACC/AHA Guidelines
CHD or High Cardiac Risk
Patients Currently Taking
Beta-Blockers
Class I*/Class IIa†, Level of Evidence: B Class I, Level of Evidence: B
— Class I, Level of Evidence: C
— Class I, Level of Evidence: C
iple, randomized, clinical trials; B data derived from a single randomized trial or nonrandomized
d to have coronary ischemia on pre-operative testing. †Applies to patients found to have coronarydenceg to
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May 20, 2008:1913–24 Pre-Operative Risk Assessmentf perioperative cardiovascular complications is far greater
han the risk of statin-induced myopathy and rhabdomyol-
sis, the potential benefits of perioperative statin use appear to
utweigh the potential hazards. It has to be noticed that these
bservations need confirmation in large randomized trials.
OSAGE AND TIMING. The optimal dosing and timing of
tatins for the prevention of perioperative events has still to
e elucidated. An important concern is the continuation of
tatins in the perioperative period. Unintended interruption
n the immediate post-operative period is a well-known
henomenon because of the unavailability of an intravenous
ormula of statins. From patients with CAD, it is known
hat sudden withdrawal of statin therapy can be harmful
77,78). Recently, it has been demonstrated in vascular
urgery patients that statin discontinuation was associated
ith an increased risk for post-operative troponin release
hazard ratio [HR] 4.6, 95% CI 2.2 to 9.6) and the
ombination of MI and cardiovascular death (HR 7.5, 95%
I 2.8 to 0.1) (79). Furthermore, they observed that the
xtended release of fluvastatin appeared to have beneficial
ffects over other statins when discontinued. The increased
ost-operative risk associated with the withdrawal of statins
as also observed by Le Manach et al. (80). These findings
ndicate that statins with a prolonged half-life time or with
n extended release formula should be preferred.
Following the available evidence of both beta-blockers
nd statins in the perioperative period, the question arises
hether these medications should be used as a combination
herapy. Some retrospective studies have already reported a
eneficial effect of using both beta-blockers and statins on
erioperative outcome (81). The previously mentioned
ECREASE-IV trial could give more insights in this topic
s it aims to assess the clinical efficacy of beta-blocker,
tatin, and combination therapy in patients undergoing
ajor noncardiac surgery (64).
cetylsalicylic acid. Acetylsalicylic acid (ASA) is one of
he cornerstones in the primary and secondary prevention
f cardiovascular diseases. Furthermore, the combination of
SA and clopidogrel is commonly used for the prevention
f stent thrombosis. The evidence of ASA in the perioper-
tive period in patients undergoing noncardiac surgery is
ess clear. In a randomized trial of patients undergoing
arotid endarterectomy, ASA was shown to be effective in
reventing intraoperative and post-operative stroke but with
o effect on death or MI (82). In another trial comparing
ow-dose and high-dose ASA in carotid surgery, results
ndicated reduced mortality, MI, and stroke in the low-dose
roup (83). A meta-analysis by Robless et al. (84) in 2001
emonstrated a reduction of serious vascular events and
ascular death in patients with peripheral vascular disease.
hat study included 10 trials of antiplatelet treatment in
ower limb bypass surgery, of which 6 involved ASA
reatment. However, the benefit of antiplatelet therapy did
ot reach statistical significance for the combined end point
f vascular events (OR 0.76, 95% CI 0.54 to 1.05) in that oascular surgery population. Concerns of promoting periop-
rative hemorrhagic complications often withheld continu-
tion of ASA in the perioperative period. No randomized
ontrolled trials exist, however, on pre-operative discontin-
ation of ASA. A meta-analysis by Burger et al. (85)
oncluded that ASA should be discontinued only if low-
ose ASA may cause bleeding risks with increased mortality
r if sequels are similar to the observed cardiovascular risks
fter ASA withdrawal. In 41 studies they observed that
SA increased the risk of bleeding complications 1.5-fold
ut did not lead to higher severity levels of bleeding
omplications. A systematic review in subjects at risk for or
ith CAD demonstrated that ASA nonadherence/
ithdrawal was associated with a 3-fold higher risk of major
dverse cardiac events (OR 3.14, 95% CI 1.75 to 5.61;
 0.0001) (86).
onclusions
n the growing elderly population with an increased cardio-
ascular comorbidity, underlying ischemic heart disease in
urgical patients is becoming a key problem. Myocardial
nfarctions are the major cause of perioperative morbidity
nd mortality. The pathophysiology of PMI is related to the
tress of surgery, inducing an oxygen supply/demand imbal-
nce in the presence of a coronary artery stenosis or a sudden
oronary plaque rupture with thrombosis and vessel occlu-
ion. In the latter condition, inflammation plays a major
ole. To prevent these devastating conditions from multi-
lying, systemic strategies are required. Beta-blockers cor-
ect the imbalance between myocardial oxygen supply and
emand, and statins and aspirin focus on plaque stabiliza-
ion by a reduction of the inflammatory response. Moreover,
urrent data clearly reveal a shift from pre-operative coro-
ary revascularization toward intensified medical treatment.
urrent recommendations of prophylactic coronary revas-
ularization have been restricted to the same indications as
n the nonoperative setting. In cardiac-stable patients,
oninvasive cardiac stress testing is therefore indicated only
f it will change management. In high-risk patients, pro-
hylactic coronary revascularization might be switched to
ater post-operative revascularization, preventing the delay
f surgery. The optimal timing of beta-blocker therapy
efore surgery has not been resolved yet. Beta-blockers have
oth a hemodynamic and an anti-inflammatory effect. To
btain maximum benefits of beta-blockade, therapy should
e initiated at least some days before surgery in combination
ith dose adjustments for tight heart rate control. Further-
ore, it is strongly advised to continue the beta-blocker
herapy throughout the perioperative period. The pleiotro-
ic effects of statins have also been shown to be beneficial in
atients undergoing noncardiac surgery. The pre-operative
isk assessment is an ideal opportunity to initiate lifestyle
hanges and medical therapy to lessen the impact of cardiac
isk factors to improve both perioperative and long-term
utcome.
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